Major depressive disorder (MDD) constitutes a major public health problem worldwide and affects women twice as frequently as men. Previous linkage studies have identified a 451 kb region of 2q33-35 that exhibited significant evidence of linkage to Mood Disorders among women (but not men) from families with recurrent, early-onset MDD (RE-MDD), a severe and strongly familial subtype of MDD. This 451 kb region includes CREB1, an attractive susceptibility gene for MDD and related disorders. Sequence variations in the CREB1 promoter and intron 8 have been detected that cosegregate with Mood Disorders, or their absence, in women from these families, identifying CREB1 as a sex-limited susceptibility gene for unipolar Mood Disorders. These findings implicate the cAMP signaling pathway in the pathophysiology of Mood Disorders and related conditions. Molecular Psychiatry (2003) 8, 611-618. doi:10.1038/sj.mp.4001354
Major depressive disorder (MDD) is characterized by two or more weeks of depressed mood or impaired enjoyment, accompanied by disturbances of sleep and appetite, psychomotor changes, impaired concentration, inappropriate guilt, and suicidal thoughts or actions. 1 Most epidemiologic and family studies indicate that the lifetime prevalence of MDD is between 5 and 10%, with women twice as likely to be affected as men. [1] [2] [3] Suicide, a tragic consequence of MDD, has been reported to occur in 10-15% of patients who were previously hospitalized for depression, 4 a rate of death that is three orders of magnitude greater than that reported for the American population as a whole. 5 In addition to suicide, an even greater absolute increase in age-specific mortality from natural causes has been reported for individuals who suffer from MDD and their family members. 6 The significance of these public health problems has been highlighted by two recent reports from the Surgeon General. 3, 5 In a study conducted by the World Health Organization, MDD ranked second only to ischemic heart disease as a source of disability worldwide. 7 Twin studies have demonstrated that genetic factors typically account for 40-70% of the risk for developing MDD, and adoption studies have confirmed the important role played by genetic risk factors in the development of MDD (for reviews, see US Department of Health and Human Services 3 ; Zubenko et al 6 ). Early age at onset of the first major depressive episode, as well as recurrence, are independent factors that increase the morbid risk of MDD among family members. In a recent study of 81 extended families (407 first-degree relatives and 835 extended relatives) ascertained through adult probands with recurrent (X2 episodes), early-onset (onset p25 years) MDD (RE-MDD), 6 over one-third of first-degree relatives and nearly one-fifth of extended relatives suffered from MDD, prevalence rates that were 7.7 and 3.8 times greater than the corresponding population rates reported by the Epidemiologic Catchment Area Study. 2 The results of a genetic segregation analysis of this sample suggest that a major locus contributes to the expression of depressive disorders within families identified by probands with RE-MDD, 8 and favored a dominant or codominant model of transmission. Furthermore, the absence of aggregation of Bipolar I Disorder (also called Manic-Depressive Illness) in these families strongly suggests that the genetic determinants of unipolar and bipolar disorders are not identical. 6 These observations illustrate the advantage of employing families identified by probands with RE-MDD in studies to identify susceptibility genes for MDD and related disorders.
Model-free linkage analysis of a region of chromosome 2q33-35, initially highlighted by our case-control studies, 9 has revealed evidence of sexspecific linkage (LOD score X3.0) to unipolar Mood Disorders extending over 15 cM in our 81 RE-MDD pedigrees. 10 Peak multipoint LOD scores of 6.33 and 6.87 occurred at D2S2321 and D2S2208, respectively. This finding resulted from linkage of the 2q33-35 region to Mood Disorders among the women in these 81 RE-MDD families; no evidence of linkage of the 2q33-35 region to Mood Disorders was detected among the male family members (peak LOD score 0.00). The 451 kb region between the adjacent SSTRPs D2S2321 and D2S2208 includes an attractive candidate gene, CREB1.
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The CREB1 gene encodes a 43 kDa cAMP-responsive element-binding protein (CREB) consisting of 341 amino acids (aa) that is a member of the basic leucine zipper family of transcription factors. 12 In addition to the full length, 341 aa CREB protein (isoform B), additional isoforms are synthesized by alternative mRNA splicing that are tissue-specific and differentially expressed during development. In response to elevated cAMP levels produced by the activation of g-protein-coupled receptors, catalytic subunits of protein kinase A diffuse into the nucleus and induce cellular gene expression by phosphorylating CREB at Ser133. Phosphorylated CREB molecules induce the transcription of genes whose promoters include a cAMP-responsive element (CRE), a conserved palindromic eight-nucleotide sequence (TGACGTCA) or single CGTCA motif. In addition to the cAMP signaling system, several growth factor and stress signals stimulate CREB-mediated transcription by promoting the phosphorylation of CREB at Ser133 by various cellular kinases. 12 Promoter sequences in addition to CRE and the participation of coactivation factors impose specificity on the particular programs of gene expression that are initiated by CREB.
CREB1 is an excellent candidate for a susceptibility gene, alleles of which might alter CREB1 gene expression or encode CREB protein variants that influence the risk of developing unipolar Mood Disorders. Alterations in CREB1 gene expression and CREB phosphorylation have been reported in clinicopathologic studies of temporal cortex from patients with MDD, in the hippocampus and nucleus accumbens of animal models of MDD and related disorders, and in the brains of rodents exposed to chronic treatment with antidepressant drugs. [13] [14] [15] CREB has also been implicated in neuronal plasticity, cognition, and long-term memory, 16 abnormalities of which commonly occur in patients with MDD, may predispose patients to the onset or recurrence of MDD, and may be related to the eventual development of irreversible dementia in some patients. 6, 17 Finally, reports of synergistic interactions of CREB with nuclear estrogen receptors [18] [19] [20] may provide a mechanism by which CREB facilitates sex-specific patterns of gene expression that manifest themselves in the sex specificity of the susceptibility locus for Mood Disorders identified by our linkage study.
In this report, we describe the identification of sequence variations in the CREB1 promoter and intron 8 that cosegregate with Mood Disorders, or their absence, in women from our collection of RE-MDD families. These findings identify CREB1 as a sex-limited susceptibility gene for unipolar Mood Disorders, and implicate the cAMP signaling pathway in the pathophysiology of Mood Disorders and related conditions.
Subjects and methods
Clinical characterization of subjects and families A total of 81 families were ascertained through adult probands with unipolar, nonpsychotic RE-MDD and included 407 first-degree relatives and 835 extended relatives, as previously described. 6 Selection criteria for families also included two living parents and at least one sibling who were willing to participate. Families were ascertained without consideration of the psychiatric diagnoses of any family member other than the proband.
Psychiatric diagnoses for probands with RE-MDD and their family members who provided blood samples were formulated from structured personal interviews, including the SADS-L 21 or the Kiddie-SADS-Epidemiologic Version, 22 structured family history assessments, and available medical records. The remaining family members who participated and those who were deceased were evaluated through the family history method augmented by available medical records. 23, 24 The inter-rater reliability of the psychiatric diagnoses established from structured personal interviews, as well as the sensitivity and specificity of the family history method to detect accurately the presence or absence of mood disorders in these groups, has been established. 6 All clinical assessments were performed by experienced mental health clinicians with regular supervision by an ABPN-certified faculty psychiatrist. Best estimate diagnoses were made using a consensus conference approach according to Research Diagnostic Criteria 25, 26 and the DSM-IV criteria. 1 This research project and associated recruitment materials were approved by the Institutional Review Board of the University of Pittsburgh. All subjects provided written informed consent prior to participation.
DNA isolation and amplification
Venous blood samples were obtained by antecubital phlebotomy by qualified clinical staff who coded the samples prior to transport to the laboratory. Lymphocytes were isolated under sterile conditions by centrifugation on an Histopaque-1077 step gradient according to the manufacturer's instructions (Sigma Chemical, St. Louis, MO, USA), and lymphoblast cell lines were established by exposure of lymphocytes to Epstein-Barr virus. Genomic DNA was isolated from whole blood or blood cells using minor modifications of standard methods as previously described.
27
CREB1 cosegregate with depressive disorders in women GS Zubenko et al DNA templates for sequencing CREB1 regions were produced by PCR amplification of genomic DNA as previously described, 28 employing oligonucleotide primers developed using the program Primer3 (URL http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi) 29 and synthesized by Invitrogen Custom Primers (Carlsbad, CA, USA). All amplification reactions used an annealing temperature of 601C. The exons were amplified using 30 s of extension and 30 rounds of amplification, whereas the promoter was amplified using 2 min of extension and 40 rounds of amplification in the presence of 5% DMSO (Sigma, St Louis, MO, USA). The oligonucleotide primers used for PCR amplification, oriented 5 0 to 3 0 , are shown Table 1 .
DNA sequencing
Automated sequencing of the GC-rich CREB1 promoter (including the untranslated regulatory region of exon 1) was performed using Applied Biosystems BigDyet chain termination chemistry (Applied Biosystems, Foster City, CA, USA) and the resulting reaction products were analyzed using an ABI PRISM s 3100 Genetic Analyzer. Manual sequencing of the 5 0 end of the CREB1 promoter and exons 2-9 was performed using the Sequenase Version 2.0 PCR Product Sequencing Kit (USB Corporation, Cleveland, OH, USA) with minor adjustments to the manufacturer's protocol. For each exon, 10 pmol of primer was annealed to the DNA template. The labeling reaction was carried out on ice for 5 min, using a 1 : 7-fold dilution of dGTP Labeling Mix and 5.0 mCi of [aÀ 35 S]dATP (Perkin-Elmer Life Sciences, Inc., Boston, MA, USA). The termination reactions were carried out for 5 min at 371C. For sequencing promoter regions, 20 pmol of primer was annealed to the DNA template. The labeling reaction was carried out on ice for 5 min using a 1 : 5-fold dilution of a labeling mix consisting of 7.5 mM each of dATP, dTTP (Amersham Biosciences, Piscataway, NJ, USA), 7-deaza-dGTP (Roche Diagnostics Corporation, Indianapolis, IN, USA), and 5.0 mCi of [aÀ 35 S]dCTP (Amersham Biosciences, Piscataway, NJ, USA), in the presence of 5% DMSO (Sigma, St Louis, MO, USA). The termination reactions were carried out using the Termination Mixes for 7-deaza-dGTP for 5 min at 371C. The resulting sequencing products were resolved on 6% denaturing polyacrylamide gels (EZ Squeezet Gene-PAGE PLUSt, Amresco, Inc., Solon, OH, USA), dried under vacuum at 801C, and visualized by autoradiographic exposure of Kodak BioMax MR film (Eastman Kodak Company, Rochester, NY, USA).
RFLP-based genotyping RFLP-based genotyping of the identified CREB1 polymorphisms was performed by PCR amplification of the polymorphic region, followed by digestion of the amplified products with a restriction endonuclease whose recognition site was eliminated by the polymorphism of interest. In each case the primer nearer the polymorphism was end labeled with 32 P, as previously described. 28 For both polymorphisms, the annealing step in the PCR reactions was performed at 601C and, for the promoter SNP, the reaction included 5% DMSO (Sigma, St Louis, MO, USA). Amplification of the region containing the promoter SNP was performed using the unlabeled forward primer (5 0 to 3 0 ) GTA GGA TGG GGC ATA TTT CCA G and the labeled reverse primer CGG GTT TTC CTT TCC GAG ACT CC. Digestion of the 192 bp product amplified from individuals who are homozygous for the wildtype allele with 5 U of MspI for 2 h at 371C yields a labeled 62 bp fragment. Destruction of the recognition site for MspI (5 0 -CCGG-3 0 ) by the G-A variant produces a labeled 108 bp fragment from individuals who are homozygous for the variant allele (none detected). Heterozygotes yield both labeled fragments. Amplification of the region containing the C deletion in intron 8 was performed using the labeled forward primer TGT TGG TTG CTG TGA GCT ATT TC, and the unlabeled reverse primer TGT TTA TTT TGT CTT TCA GGT TGT GG. Digestion of the 327 bp product amplified from individuals who are homozygous for the wild-type allele with 2.5 U of MnlI for 2 h at 371C yields a labeled 102 bp fragment. Destruction of the recognition site for MnlI (5 0 -CCTC-3 0 ) by the C deletion produces a labeled 197 bp fragment from individuals who are homozygous for the variant allele (none detected). Heterozygotes yield both labeled fragments. Restriction endonucleases were purchased from New England Biolabs (Beverly, MA, USA). Digestion products were resolved on 6% denaturing polyacrylamide gels, dried under vacuum at 801C, GCT TTC TGT GAG TTT TCT CAT  TGG CAC TTG TAT TGG TTT CTC TG  Exon 7  TGA TGT TAT TTG CTG TAA CTT CTC CT  TGG TGG TTT GCA ATA TGA TAC TTA CT  Exon 8  TCC AAA ATA CAT GCT TAG ATT GAT GA  GCA GAA TGT GAA GAC ACA CTT AAC AC  Exon 9  TGT TGG TTG CTG TGA GCT ATT TC  TGT TTA TTT TGT CTT TCA GGT TGT GG and visualized by exposure of Kodak BioMax MR film.
Linkage analysis procedures
Identity-by-descent (IBD)-sharing estimates for the marker loci were obtained with the GENIBD program from the S.A.G.E. (Statistical Analysis for Genetic Epidemiology) package, release 4.2. 30 Both singlemarker and multipoint IBD-sharing distributions were generated. Single-marker IBD analysis generated IBDsharing estimates for relative pairs using complete marker information. Multipoint IBD-sharing distributions were calculated at each of the markers using the exact algorithm implemented in GENIBD when the quantity 2[(number of nonfounders)-(number of founders)] in the pedigree was 18 or less. The exact algorithm is based on the Lander-Green multipoint algorithm. 31 Multipoint IBD-sharing estimates in other pedigrees were calculated with GENIBD using the modified Markov chain Monte Carlo (MCMC) simulation algorithm of Sobel and Lange. 32 Model-free linkage analysis was performed for all affected relative pairs using the LODPAL program of the S.A.G.E. 4.2 software package. LODPAL performs the analysis with the general conditional logistic model, 33 a reparameterized version of the LOD score model for affected-sib-pair linkage, 34 which allows for the inclusion of covariates and all affected relative pair types in the linkage analysis. Multipoint analyses were performed using the modified one-parameter model of the conditional logistic model 35 and employed the IBD-sharing estimate at each marker position. Linkage analysis was performed in all relative pairs followed by sex-specific pairs. Sexaveraged marker map distances were used for the analyses that included all affected relative pairs, while sex-specific map distances were used for the separate analyses of female or male pairs, 36 as previously described. 10 
Results
In view of the attractiveness of CREB1 as a sexspecific candidate susceptibility gene, we sequenced the CREB1 coding regions (1026 total bps), splice junctions of all 9 exons, and the 5' regulatory regions (À1004 to 173 bps), of all affected or unaffected women from RE-MDD family A (Figure 1 ) with the goal of identifying sequence variants that were associated with the development of unipolar Mood Disorders. The nucleotide sequences of the CREB1 exons and flanking regions were provided in the databases of the National Center for Biotechnology Information 11 , while the promoter region was defined by Meyer et al 37 and is numbered relative to the major transcription initiation site. In our previous linkage study, 10 family A yielded a peak multipoint LOD score of 3.77 at D2S2208 for female relative pairs affected by unipolar Mood Disorders, and had the potential to generate a significant LOD score between a variant CREB1 allele that was cosegregating with Mood Disorders (or their absence).
These efforts revealed single base changes at two locations within the CREB1 gene, both of which were associated with the affected phenotype. As shown in Figure 2a and b, the first of these was a G-A transition located at position À656 that eliminates a consensus binding motif for AP-2, a transcriptional activator, and a potential CpG methylation site, in the CREB1 promoter. The second was a C deletion in intron 8, 16 bases before the initiation of exon 9, the final exon of CREB1, as shown in Figure 3a and b. The validity of these sequence variants was confirmed using independently amplified templates of the CREB1 promoter that were sequenced in both directions. Both variants were identified repeatedly among the female members of family A and conformed to the expectations for Mendelian segregation.
Genotyping all remaining members of the 31 RE-MDD families that previously revealed positive LOD scores with the 2q33-35 locus for these CREB1 variants was facilitated by the use of RFLP assays that detected the presence/absence of an MspI restriction site that was eliminated by the G-A transition (Figure 2c ), or the presence/absence of an Mnl I restriction site that was eliminated by the C deletion (Figure 3c ). One additional family (family B) in which the promoter SNP at À656 was segregating was identified by this screen and is presented along with family A in Figure 1 . The identical base change in the members of family B was confirmed by DNA sequencing. No additional families segregating the C deletion in intron 8 were found.
All family members who carried these CREB1 variants were heterozygous, and the CREB1 alleles (wild type, promoter variant, intron 8 variant) were transmitted independently. Model-free linkage analysis of the promoter SNP with Mood Disorders in these two families was performed with sex as a covariate, as previously described, 10 and revealed a significant LOD score of 5.42. Heterozygosity for the CREB1 promoter variant was strongly associated with the diagnosis of a Mood Disorder among women (w 2 ¼ 9.76, df ¼ 1, P ¼ 0.002), but not men (exact In contrast to the CREB1 promoter variant, heterozygosity for the C deletion in intron 8 exhibited a protective effect against the development of Mood Disorders among women in this family (exact P ¼ 0.01), but not men (exact P ¼ 1.00). Nine (82%) of the 11 women who carried the risk allele were affected but, since one of these carriers had not yet lived through the age of risk for MDD, the penetrance of this risk allele may exceed 82%. All six of the women who carried the protective allele were unaffected. These findings are consistent with a sexlimited autosomal dominant or codominant model of inheritance with incomplete penetrance. However, small effects in men cannot be entirely excluded because of the relatively smaller numbers of affected men in our study population. The two CREB1 sequence variants contributed to the susceptibility of Mood Disorders in only 2 (6.5%) of the 31 RE-MDD families that yielded positive LOD scores, or 2.5% of the 81 RE-MDD families in our collection. To determine whether families A and B accounted entirely for the evidence of linkage in this region of 2q33-35, 10 the linkage analysis was repeated using the 79 RE-MDD families that remained after eliminating families A and B. As shown in Figure 4a , the 79 remaining families generated a statistically significant maximum LOD score of 4.24 that occurred at the same 451 kb region that contains CREB1. Since the covariate for sex also remained significant (Po0.0001), linkage analysis was performed independently for affected female or male relative pairs. As shown in Figure 4b , the residual evidence of linkage remained exclusively among the female affected pairs. These results suggest that additional female-specific CREB1 susceptibility alleles remain to be detected within the 81 RE-MDD families.
Discussion
The significance of these results is manifold. They highlight the role of the cAMP signaling pathway, and CREB in particular, in the pathophysiology of unipolar Mood Disorders, especially in women. These findings also suggest that the genes for other components of this signaling pathway, as well as the target genes whose expression they regulate, may also harbor alleles that affect the development of Mood Disorders and related conditions. As an example, the Rubinstein-Taybi syndrome results from autosomal dominant mutations in a gene located on chromosome 16p13.3 that encodes the CREB-binding protein (CBP), a transcriptional co-activator. 38 In addition to mental retardation and characteristic physical features, this syndrome is frequently accompanied by Mood and Anxiety Disorders. 38, 39 The more extensive developmental manifiestations of the RubinsteinTaybi syndrome appear to result from mutations or microdeletions in coding regions that physically alter the CBP protein 38 and disrupt its histone acetyltransferase activity. 40, 41 In addition to the cAMP signaling pathway, growth factors and stress signals stimulate CREB-mediated transcription by promoting the phosphorylation of CREB, 12 and may also contribute to the molecular cascade that influences the development of Mood Disorders and related conditions. Preclinical studies that explore the functional significance of these CREB1 alleles, and clinical studies that employ individuals who carry these susceptibility alleles, seem likely to advance our understanding of the clinical biology and experimental therapeutics of Mood Disorders. Transgenic mice that bear CREB1 susceptibility alleles may also provide relevant animal models. By analogy, considerable insight into the pathophysiology of typical forms of Alzheimer's disease (AD) has been gleaned from studies that examined the effects of rare autosomal dominant mutations that confer risk for early-onset, familial AD, and account for only a small fraction (o1%) of all AD cases. 42 The sex-specificity of the CREB1 susceptibility alleles suggests that there may be important differences in the molecular pathophysiology of Mood Disorders in men and women, or in the mechanisms that determine resilience to endogenous or environmental depressogenic stimuli. Several lines of phenomenological, clinical, and biological evidence are consistent with this hypothesis. 10 These differences may contribute to the vulnerability of women to the development of disturbances of mood during times of significant hormonal fluctuation including puberty, menstrual cycling, pregnancy and childbirth, and menopause. Further refinement of the clinical syndrome whose development is influenced by this susceptibility locus is an important area for future study. A substantial proportion of the members of the 81 families employed in this study met diagnostic criteria for additional 'comorbid' psychiatric disorders including Alcohol and Drug Use Disorders, Anxiety Disorders, and Personality Disorders, which share prominent clinical features with Mood Disorders. 6 Individuals in these families also appear to suffer from an increased risk of disorders usually first apparent in infancy, childhood, or adolescence, as well as Alzheimer-like dementia in late life. 6 Whether the identified susceptibility locus for Mood Disorders influences the development of other psychiatric disorders that aggregate in the families of RE-MDD probands remains to be determined. However, a preliminary case-control study has suggested that the 124 bp allele of D2S2944 may be associated with Alcohol and possibly other Substance Use Disorders in addition to Mood Disorders. 28 Broadening the definition of the affected phenotype in our analysis of families A and B to include Alcohol or other Substance Use Disorders did not provide additional evidence of cosegregation with the CREB1 variants. Further refinement of the clinical syndrome whose development is influenced by this and other susceptibility loci, as well as the sex specificity of the phenotypes, will be addressed more fully in future studies.
The identified variants of the ubiquitously expressed CREB1 gene may also exert pleiotropic effects outside of the central nervous system (that may or may not be sex specific). The deceased members of the 81 RE-MDD families died at a median age that was 8 years earlier than for the reference population; over 40% died before reaching age 65. 6 This difference in mortality resulted from a shift towards younger ages at death across the lifespan, including a five-fold increase in the proportion of individuals who died in the first year of life. Several-fold increases in the proportion of deaths by suicide, homicide, and liver disease were observed among the relatives of RE-MDD probands. However, the rank order of the three most common causes of death, heart disease, cancer, and stroke, remained unchanged from the reference population, and differences in the proportions of deaths from the remaining causes were small. Future family and genetic epidemiologic studies will explore the potential role of this locus in the excess mortality suffered by these individuals and its causes across the life span.
Finally, these results have implications for future efforts to identify additional susceptibility genes for unipolar Mood Disorders and other common multifactorial human disorders whose genetic underpinnings are complex. The use of analytic approaches that do not rely upon particular modes of inheritance and that have the capacity to detect alleles with different effects in women and men seem prudent. Futhermore, even the most ambitious collections of affected sib pairs have insufficient statistical power to identify highly-penetrant dominant/codominant susceptibility alleles that are segregating in less than 20-25% of families. The strategy of including large families that individually have sufficient power to detect linkage can overcome the gene-hunting challenge imposed by potential genetic heterogeneity across families.
